Home » Atara Scoops Up FDA Orphan Drug Status for T-lymphocyte Candidate
Atara Scoops Up FDA Orphan Drug Status for T-lymphocyte Candidate
Atara Biotherapeutics has won orphan drug designation for its T-lymphocyte product candidate activated against Epstein-Barr Virus for the treatment of patients with EBV post-transplant lymphoproliferative disorder following hematopoietic cell transplant or solid organ transplant.
The candidate is on track to start Phase 3 studies, according to the company.
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct